Get the Stockscreener App
1.815
0.27%
-0.005
Artelo Biosciences Inc stock is traded at $1.815, with a volume of 4,000.
It is down -0.27% in the last 24 hours and up +21.81% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
4,000
Relative Volume:
0.01
Market Cap:
$3.66M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.5744
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
+6.14%
1M Performance:
+21.81%
6M Performance:
-86.97%
1Y Performance:
-74.58%
1-Day Range:
$1.81
$1.85
1-Week Range:
$1.65
$1.8791
52-Week Range:
$1.15
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.815 | 3.67M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.73 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.20 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
848.39 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.04 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.18 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Stock Analysis: Is Artelo Biosciences Inc impacted by rising ratesWeekly Trade Review & Accurate Intraday Trading Signals - baoquankhu1.vn
Can Constellation Brands Inc lead its sector in growthWeekly Risk Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Artelo Biosciences adjourns and reschedules 2025 annual meeting - MSN
Market Leaders: Is KORE attractive at current valuationJuly 2025 Outlook & Reliable Trade Execution Plans - baoquankhu1.vn
Artelo Biosciences faces new Nasdaq compliance challenges - TipRanks
Artelo Biosciences Received Notice of Noncompliance - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
How Artelo Biosciences Inc. stock reacts to inflationary pressuresDaily Trainer Picks & support options for steady strides - ulpravda.ru
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - FinancialContent
D. Boral Capital Downgrades Artelo Biosciences (ARTL) - MSN
What makes Inno Holdings Inc. stock price move sharply - ulpravda.ru
Can Artelo Biosciences Inc. stock sustain free cash flow growthTrade Volume Report & Free Community Consensus Stock Picks - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Is Artelo Biosciences Inc. stock a buy in volatile marketsJuly 2025 Technicals & Growth Focused Entry Point Reports - Улправда
Star TribuneArtelo Biosciences, Inc.Common Stock (Nasdaq:ARTL) Stock Quote - FinancialContent
How strong is Artelo Biosciences Inc. stock balance sheetCPI Data & Capital Protection Trading Alerts - ulpravda.ru
Artelo Biosciences Inc Stock Analysis and ForecastCandlestick Trading Patterns & Best Stocks For Explosive Growth - earlytimes.in
Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Average Recommendation of “Hold” by Analysts - Defense World
Bank Watch: Can Artelo Biosciences Inc stock deliver 10 annual returnsQuarterly Market Summary & Reliable Price Breakout Alerts - moha.gov.vn
Is Artelo Biosciences Inc a good long term investmentAI-Driven Market Analysis & Explosive Growth Opportunities - earlytimes.in
Artelo Biosciences adjourns annual meeting due to lack of quorum - Investing.com
Artelo Biosciences Adjourns and Reschedules 2025 Annual Meeting - TipRanks
Artelo Biosciences adjourns annual meeting due to lack of quorum By Investing.com - Investing.com South Africa
Artelo Biosciences Adjourns and Reschedules Annual Meeting - TradingView — Track All Markets
Technical Analysis: How strong is Artelo Biosciences Inc stock balance sheetQuarterly Profit Report & Scalable Portfolio Growth Ideas - Bộ Nội Vụ
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate - The Manila Times
Medicare moves to test medical CBD — one firm readies a lab-grade pill - Stock Titan
Artelo Biosciences launches public offering; shares down 10% - MSN
Why Artelo Biosciences Inc. stock is favored by top institutionsTrade Volume Report & Free Expert Verified Stock Movement Alerts - Улправда
ARTL (Artelo Biosciences) EV-to-OCF : -0.31 (As of Dec. 22, 2025) - GuruFocus
Geopolitics Watch: Why Artelo Biosciences Inc. stock is favored by top institutions2025 Pullback Review & Free Safe Capital Growth Stock Tips - Улправда
Artelo Biosciences launches underwritten public offering to raise capital - MSN
Artelo Biosciences Earnings Notes - Trefis
Mark Edward Spring Net Worth (2025) - GuruFocus
Artelo Biosciences files to sell 899,972 shares of common stock for holders - MSN
Artelo Biosciences, Inc. (ARTL) 6.68% in After-hours: Following Strong Business Update - Stocks Telegraph
Artelo Biosciences Revises Bylaws, Alters Governance Structure - MSN
Artelo Biosciences (ARTL) Stock: Faces Market Reaction After Positive Research on Stress Relief Treatments - parameter.io
Unexpected Movements: Artelo Biosciences’ Stock Dynamics - timothysykes.com
Artelo Biosciences (ARTL) Research Highlights Potential of FABP5 Inhibitor in Stress Management - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of A Novel Fatty Acid Binding Protein 5 Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Mod - marketscreener.com
Artelo (Nasdaq: ARTL) study: FABP5 inhibitor reduces anxiety, depression in rats - Stock Titan
Artelo Biosciences, Inc. (ARTL) -5.56% in After-hours: Stock Declines Amid Routine Trading - Stocks Telegraph
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Will Artelo Biosciences Inc. stock see insider buyingJobs Report & AI Driven Stock Movement Reports - Newser
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
What's going on in today's after hours session - Chartmill
What analysts say about Artelo Biosciences Inc stockMACD Histogram Signals & Target Triple-Digit Stock Opportunities - earlytimes.in
Artelo Biosciences Appeals Nasdaq Delisting Decision - MSN
Artelo Biosciences (NASDAQ:ARTL) Given “Hold” Rating at Maxim Group - Defense World
Artelo Biosciences Inc. stock trend forecast2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
2.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):